Similarly, post-hoc analyses of biomarker data from a phase 3 trial in mild probable AD (MMSE 20–26), revealed that baseline plasma NfL was significantly associated with change over the course of the18-month trial on clinical scales of cognition and function, whereas no such association was observed for T-tau [28]. Here, MAPT is linked to Alzheimer disease.